|
US 11,987,574 B2 |
|
| MK2 inhibitors and uses thereof |
| Lynnie Trzoss, San Diego, CA (US); Qing Dong, San Diego, CA (US); Stephen W. Kaldor, Foster City, CA (US); and Robert L. Hoffman, San Diego, CA (US) |
| Assigned to XinThera, Inc., Foster City, CA (US) |
| Filed by XinThera, Inc., Foster City, CA (US) |
| Filed on Jul. 13, 2023, as Appl. No. 18/352,078. |
| Application 18/310,943 is a division of application No. 17/868,567, filed on Jul. 19, 2022, granted, now 11,680,056, issued on Jun. 20, 2023. |
| Application 18/352,078 is a continuation of application No. 18/310,943, filed on May 2, 2023. |
| Application 17/868,567 is a continuation of application No. PCT/US2022/022525, filed on Mar. 30, 2022. |
| Claims priority of provisional application 63/318,118, filed on Mar. 9, 2022. |
| Claims priority of provisional application 63/168,407, filed on Mar. 31, 2021. |
| Prior Publication US 2023/0373969 A1, Nov. 23, 2023 |
| This patent is subject to a terminal disclaimer. |
| Int. Cl. C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01) |
